Equities analysts expect that Prothena Co. PLC (NASDAQ:PRTA) will post $220,000.00 in sales for the current quarter, Zacks reports. Two analysts have made estimates for Prothena’s earnings. The highest sales estimate is $230,000.00 and the lowest is $200,000.00. Prothena reported sales of $280,000.00 during the same quarter last year, which indicates a negative year-over-year growth rate of 21.4%. The firm is expected to issue its next earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Prothena will report full year sales of $780,000.00 for the current year, with estimates ranging from $700,000.00 to $860,000.00. For the next fiscal year, analysts expect that the company will post sales of $48.45 million, with estimates ranging from $45.90 million to $51.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Prothena.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.60) by $0.08. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.20 million. Prothena had a negative return on equity of 33.45% and a negative net margin of 13,978.88%.

A number of analysts have commented on PRTA shares. Barclays set a $145.00 price target on Sanderson Farms and gave the stock a “hold” rating in a research report on Friday, May 31st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Prothena in a research report on Thursday, May 16th. Zacks Investment Research cut CGI from a “buy” rating to a “hold” rating in a research report on Wednesday, June 19th. BidaskClub cut Weyco Group from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 13th. Finally, ValuEngine cut Zumiez from a “hold” rating to a “sell” rating in a research report on Monday, May 13th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $11.26.

Shares of Prothena stock traded up $0.21 during trading on Wednesday, reaching $9.93. The company’s stock had a trading volume of 165,251 shares, compared to its average volume of 160,147. The company has a debt-to-equity ratio of 0.07, a quick ratio of 27.85 and a current ratio of 27.85. The stock has a market capitalization of $387.48 million, a P/E ratio of -2.75 and a beta of 2.33. Prothena has a 1-year low of $8.63 and a 1-year high of $15.91. The company has a 50-day moving average price of $9.85.

Institutional investors and hedge funds have recently modified their holdings of the business. Quantamental Technologies LLC lifted its position in Prothena by 142.9% during the 1st quarter. Quantamental Technologies LLC now owns 4,129 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 2,429 shares during the period. SG Americas Securities LLC purchased a new position in shares of Prothena during the 1st quarter valued at about $114,000. BNP Paribas Arbitrage SA raised its stake in shares of Prothena by 309.5% during the 1st quarter. BNP Paribas Arbitrage SA now owns 11,061 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 8,360 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Prothena by 7.5% during the 4th quarter. Legal & General Group Plc now owns 14,611 shares of the biotechnology company’s stock valued at $151,000 after buying an additional 1,024 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale raised its stake in shares of Prothena by 22.1% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 15,450 shares of the biotechnology company’s stock valued at $240,000 after buying an additional 2,800 shares during the last quarter. 98.93% of the stock is owned by institutional investors.

Prothena Company Profile

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.

Featured Story: Why is the LIBOR significant?

Get a free copy of the Zacks research report on Prothena (PRTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.